Chiwoo Oh: AS01B Adjuvant and Long-Term Immune Reprogramming After Shingrix Vaccination
Chiwoo Oh, Postdoctoral Research Fellow at Harvard Medical School, shared a post on LinkedIn about recent article by Fabiana Corsi-Zuelli et al, published in Nature Medicine, adding:
“The AS01B adjuvant (MPL plus QS 21) in Shingrix initially induces strong innate immune activation but subsequently causes long term reprogramming of the chromatin and transcriptional state of monocytes, reducing inflammatory cytokine responses such as IL6 upon subsequent TLR stimulation.
This may, in turn, decrease chronic vascular and atherosclerosis-associated inflammation, potentially lowering the risk of cardiovascular events.”
Title: Recombinant shingles vaccination and the risk of cardiovascular events
Authors: Fabiana Corsi-Zuelli, Fang Li, Rachel Upthegrove, John A. Todd, Betty Raman, Paul J. Harrison, Maxime Taquet
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 17, 2026, 17:27John Strouse: Building Standards for Whole-Person Sickle Cell Care Through Collaboration
-
Oct 17, 2026, 17:20Jean-Jacques Kiladjian: Exploring the Future of Polycythemia Vera Treatment at MPN Horizons 2026
-
Oct 17, 2026, 17:10Habib Bennaceur: Strengthening Collaboration in Haemophilia, Sickle Cell Disease and Thalassaemia in India
-
Oct 17, 2026, 16:58Danny Hsu: Building Connections at the AUSNBled Collaborative Dinner in Auckland
-
Oct 17, 2026, 16:48Kalyan Roy: Enhancing Patient Experience Through Learning and Collaboration
-
Oct 17, 2026, 16:43Wilfried Dinh: Antiplatelet Therapy in 2026: Duration is Becoming a Dynamic Decision
-
Oct 17, 2026, 16:37Ian Setchfield: Dr. Evans Presents on Safe Anticoagulation Prescribing at East Kent Hospitals
-
Oct 17, 2026, 16:33Lewis Thomas: Connecting Through Shared Experiences at ASCAT 2026
-
Oct 17, 2026, 16:29Nilesh Jethwa: Yasmin Adverse Event Reports Exceed 23,000 Over Two-Year Period